Parse Biosciences Progresses Towards Launching Single-Cell Chromatin Accessibility Products
Parse Biosciences, a leading innovator in scalable and accessible single-cell sequencing technology, has reaffirmed its commitment to advancing its Evercode™ single-cell chromatin accessibility products. This announcement marks a significant milestone for the company as it continues to expand its portfolio of cutting-edge genomic tools designed to revolutionize single-cell research.
This development follows a favorable legal outcome for Parse Biosciences. Recently, the company successfully invalidated patents asserted by 10x Genomics against its Evercode Whole Transcriptome products, leading to the cancellation of a trial over those patents. In addition to this legal victory, Parse reached an amicable resolution with 10x Genomics regarding other patents that are unrelated to its existing Evercode product line or its upcoming chromatin accessibility products. With these legal matters now behind it, Parse is poised to focus entirely on innovation and delivering high-impact solutions to the research community.
A Commitment to Innovation in Single-Cell Analysis
Single-cell chromatin accessibility analysis is a crucial area of genomic research, as it provides insights into the regulatory mechanisms governing gene expression. Traditional methods, such as ATAC-seq (Assay for Transposase-Accessible Chromatin using sequencing), have been widely used for this purpose. However, these techniques often come with limitations, including data inconsistency, uneven coverage, and scalability challenges.
Parse Biosciences aims to overcome these limitations with its novel approach to chromatin accessibility analysis. By leveraging its proprietary Evercode technology, the company promises a solution that offers higher quality and more uniform data, providing researchers with unprecedented clarity in their studies of gene regulation and cellular differentiation.
The company has announced plans to launch early access to its chromatin accessibility products in late 2025, allowing select researchers to evaluate the technology before a broader commercial release. This timeline reflects Parse’s commitment to rigorous product development and validation, ensuring that its new tools meet the highest standards of scientific accuracy and reliability.
Expanding the Boundaries of Single-Cell Sequencing
Parse Biosciences has built a strong reputation in the life sciences industry for its pioneering work in single-cell sequencing. Its Evercode technology has been widely adopted by researchers worldwide, empowering them to conduct large-scale studies with unprecedented ease and accuracy.
One of the company’s most recent breakthroughs is the launch of the Evercode Penta kit, a groundbreaking advancement that enables researchers to analyze up to 5 million cells in a single experiment. This represents the largest-scale single-cell sequencing capability available to date, setting a new benchmark for the field.
By continuously pushing the limits of what is possible in single-cell analysis, Parse Biosciences is opening new avenues for discovery in diverse research areas, including cancer biology, regenerative medicine, immunology, and neuroscience. The company’s commitment to innovation ensures that scientists have access to the most advanced tools needed to address some of the most pressing questions in human health and disease.
A Vision for the Future of Genomic Research
Parse Biosciences’ mission is to accelerate scientific progress and improve human health by making single-cell sequencing more accessible and scalable. The company’s technology, originally developed at The University of Washington by co-founders Alex Rosenberg and Charles Roco, has already made a significant impact in the field.
With over $100 million in funding and a rapidly growing global customer base of more than 2,500 institutions, Parse is well-positioned to continue its trajectory of innovation and industry leadership. Its expanding portfolio of products, including Evercode Whole Transcriptome, Evercode TCR, Evercode BCR, CRISPR Detect, Gene Select, and the interactive data analysis platform Trailmaker, demonstrates its commitment to providing comprehensive solutions for researchers.
The company has also made significant investments in infrastructure to support its growth. Located in Seattle’s South Lake Union district, Parse recently expanded into a new headquarters and state-of-the-art laboratory facility. This expansion underscores its dedication to fostering cutting-edge research and development, ensuring that it remains at the forefront of the genomics revolution.
